Biotech

All Articles

AstraZeneca posts information on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed a very early consider the performance of its internal antibody-d...

iTeos- GSK's TIGIT star presents relevant improvement

.After announcing a phase 3 launch based upon good midstage end results, iTeos and GSK are actually ...

More collective FDA can increase unusual illness R&ampD: document

.The FDA should be actually more open and collaborative to release a rise in commendations of rare i...

Zenas, MBX, Bicara scalp to Nasdaq in scorching time for biotech IPOs

.It is actually an uncommonly active Friday for biotech IPOs, along with Zenas BioPharma, MBX and Bi...

Atea's COVID antiviral fails to halt hospital stays in phase 3

.Atea Pharmaceuticals' antiviral has stopped working an additional COVID-19 trial, but the biotech s...

Neurocrine's proposal to save schizophrenia possibility stops working

.Neurocrine Biosciences' schizophrenia course pivot has actually neglected. The biotech was actually...

Sanofi pays $110M upfront for late-stage radioligand treatment

.Sanofi has actually made an overdue entry to the radioligand gathering, spending one hundred millio...

F 2G increases $100M for 2nd try to obtain brand-new antifungal to market

.After F2G's initial attempt to get a new course of antifungal to market was actually wrecked due to...

Moderna targets $1.1 B in R&ampD costs slices, falls 5 courses amidst productivity pressures

.Moderna has promised to cut R&ampD costs through $1.1 billion through 2027. The choice to retract t...

Sanofi's $80M bank on Fulcrum dystrophy drug finishes in stage 3 fail

.Only four months after Sanofi wager $80 million in upfront cash on Fulcrum Rehabs' losmapimod, the ...